Patent received in Japan for its PhytoMatrix®
formulation, a supplement with all natural vitamins and plant-based
minerals
COPPELL, Texas--(BUSINESS WIRE)--Feb. 2, 2015--
Mannatech,
Incorporated (NASDAQ: MTEX),
the founder of the M5MSM
(Mission 5 MillionSM) social entrepreneurial movement,
the pioneer of nutritional glycobiology and the global innovator of
naturally sourced supplements based on Real
Food Technology® solutions, has been issued its 99th
patent, validating and demonstrating its position as the leading
developer of nutritional technology. This patent was received in Japan
for its PhytoMatrix formulation, a supplement with all natural vitamins
and plant-based minerals.
“By receiving multiple patents in multiple countries, Mannatech has
established itself around the world as the leading developer of unique,
high quality health and wellness technology,” said Dr. Rob Sinnott, CEO
and Chief Science Officer at Mannatech. “Mannatech is unique in the
nutritional supplement field for the multiple patents our products have
received around the world. This, along with product benefits established
in published human clinical trials, clearly demonstrates the soundness
of our nutrition technology. Our PhytoMatrix product is an excellent
example of how Mannatech supports overall wellness through a formulation
that provides a nutritional boost to our everyday diet*.”
The Certificate of Grant for Mannatech’s PhytoMatrix formulation in
Japan was received on Nov. 7, 2014. The patent will remain in effect for
20 years from the date of filing. There are currently seven patents
issued in major global markets to Mannatech for the technology
pertaining to its PhytoMatrix formulation.
Mannatech’s PhytoMatrix formulation has been available since 2006 and is
sold around the world. It is the only vitamin and mineral supplement on
the market that contains minerals from hydroponically grown Indian
Mustard plant and food-sourced vitamins and phytonutrients from fruits
and vegetables. The PhytoMatrix formulation is gluten-free, suitable for
vegetarian diets and is NSF
certified.
Overall, 99 patents have been issued to Mannatech in multiple global
markets for the technology pertaining to its Ambrotose®,
Ambrotose AO®, GI-ProBalance®, and
PhytoMatrix® product formulations and in the field of
biomarker assays. Because of the unique nature of Mannatech’s
technology, the company has a history of diligently and successfully
defending the strength and validity of its patents against companies
that sell infringing products.
In addition to Mannatech’s extensive patent portfolio, numerous products
have been further validated by research conducted by independent
scientists and published in peer-reviewed scientific journals. To date,
17 human clinical trials have been published, 13 of which were
double-blind, placebo-controlled studies -- the gold standard for
product validation.
Mannatech also uses the same proprietary technology found in its
PhytoMatrix and PhytoBurst® line as the vehicle to provide critical
nutrition to children around the world through its M5M℠ donation
program. Any purchase of a Mannatech product contributes in the aid of
children in need. The M5M program has given Mannatech a way to directly
provide nutrition to those most in need, a sentiment strongly supported
by Mannatech’s worldwide network of independent sales Associates.
Individuals interested in Mannatech’s products, or exploring its social
entrepreneurial efforts to help fight global childhood malnutrition, can
learn more at Mannatech.com.
Those interested in obtaining technical information and reading
published product studies may visit MannatechScience.org.
About Mannatech
Mannatech, Incorporated, develops high-quality health, weight and
fitness, and skin care products that are based on the solid foundation
of nutritional science and development standards. Mannatech is dedicated
to its platform of Social Entrepreneurship based on the foundation of
promoting, aiding and optimizing nutrition where it is needed most
around the world. Mannatech’s proprietary products are available through
independent sales Associates around the globe including the United
States, Canada, South Africa, Australia, New Zealand, Austria, Denmark,
Germany, Norway, Sweden, the Netherlands, Spain, the United Kingdom,
Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland,
Czech Republic, the Republic of Korea, Mexico, Namibia, Spain and Hong
Kong. For more information, visit Mannatech.com.
Please note: This release contains “forward-looking statements”
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally can be identified by use of phrases
or terminology such as “intend” or other similar words or the negative
of such terminology. Similarly, descriptions of Mannatech’s objectives,
strategies, plans, goals or targets contained herein are also considered
forward-looking statements. Mannatech believes this release should be
read in conjunction with all of its filings with the United States
Securities and Exchange Commission and cautions its readers that these
forward-looking statements are subject to certain events, risks,
uncertainties and other factors. Some of these factors include, among
others, Mannatech’s inability to attract and retain Associates and
Members, increases in competition, litigation, regulatory changes and
its planned growth into new international markets. Although Mannatech
believes that the expectations, statements and assumptions reflected in
these forward-looking statements are reasonable, it cautions readers to
always consider all of the risk factors and any other cautionary
statements carefully in evaluating each forward-looking statement in
this release, as well as those set forth in its latest Annual Report on
Form 10-K and Quarterly Report on Form 10-Q, and other filings filed
with the United States Securities and Exchange Commission, including its
current reports on Form 8-K. All of the forward-looking statements
contained herein speak only as of the date of this release.
*These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure or
prevent any disease.
Source: Mannatech, Incorporated
Mannatech, Incorporated
Raquel Mooring, 972-471-1532
rmooring@mannatech.com